The global allergic rhinitis market was valued at $7 billion in 2009 and is forecast to decline by 2% annually for the next seven years to reach $5.9 billion in 2016. The decline in market size is primarily due to strong competition and the entry of low cost drugs into the market. Although the disease incidence rate and prescription rate are increasing year on year, declining drug prices are will cause the market to shrink.

Medpointe Pharmaceutical, GlaxoSmithKline (GSK), Merck & Co, and AstraZeneca are the leading competitors in the global allergic rhinitis market. The competitive landscape is highly populated with 10 products, six of which can be described as significantly strong and dominating.. This market is characterized by levels of high self medication.

For further details, please click or add the below link to your browser:

http://www.global-market-research-data.com/Report.aspx?ID=Allergic-Rhinitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Approximately 56 products were in different developmental stages in 2009. Bilastine, Sublivac, Donase (Azelastine+Fluticasone), and GSK256066, are the key products currently in the pipeline. Bilastine, Donase and GSK256066 are me-too drugs that are either H1 antagonists or corticosteroids. In addition, the pipeline consists of drugs that are extracts of allergens capable of inducing an immunological response and monoclonal antibodies that are very specific to the suppression of the IgE protein that is found in elevated levels in blood during allergic rhinitis.

At present the allergic rhinitis market is highly competitive with 10 approved drugs and three generics. The dominant classes of drugs are H1 or histamine antagonists and anti-inflammatory corticosteroids. The various formulations of the above classes of drugs such as nasal sprays, tablets, capsules or aqueous suspensions serve almost all the market opportunities. The current treatment options are capable of serving the infant sector as well. At present the drugs are capable of inducing a response within eight hours after the medication. However, any new entrant that has a better response rate will capture value in the market.

For further details, please click or add the below link to your browser:

http://www.global-market-research-data.com/Report.aspx?ID=Allergic-Rhinitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData, the industry analysis specialist, has released its latest research “Allergic Rhinitis - Drug Pipeline Analysis and Market Forecasts to 2016”. The report provides key data, information and analysis on the global allergic rhinitis disease market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts for seven years to 2016. The report provides coverage of the market landscape, market drivers and restraints, and an in-depth pipeline analysis. The current competitive landscape is also analyzed and the unmet need or commercial opportunity of the market is calculated. The pipeline analysis covers molecules across all phases of clinical development and provides an overview of the developing trends among pipeline molecules, as well as an insight into the most promising pipeline drugs supplemented with key company profiles. By considering the current competition in the market and the prospects of the pipeline molecules, the resulting implications for the future market competition is also outlined.

For further details, please click or add the below link to your browser:

http://www.global-market-research-data.com/Report.aspx?ID=Allergic-Rhinitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Or Visit our report store: http://www.globaldata.com/reportstore